Editas Medicine (EDIT) Stock
Editas Medicine (EDIT) closed at $1.87 on Nov 16, 2026; its Tenet Score is 27 of 100 against 409 Healthcare peers.
Key stats
- Previous close
- $1.87
- Nov 16, 2026
- Market cap
- $288.6M
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 1.66 – 3.94
- low → high
- Tenet Score
- 27/100
- Weak · 409 Healthcare peers
Industry: Drugs · see every company filed here →
Editas Medicine, Inc. scores 27/100. Weak. Quality is the soft spot versus 409 Healthcare peers.
Tenet Score · vs sector
n=409Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
- ~ Not-a-Value-Trap Gate
13F flows & insider trades land here.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDI…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 13, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Pacific Biosciences of California, IncPACB | 40 | $613.3M |
| Climb Bio Inc.CLYM | 62 | $608.5M |
| Sana Biotechnology IncSANA | 34 | $605.3M |
| Evotec SEEVO | 51 | $561.8M |
| Capricor Therapeutics IncCAPR | 51 | $554.1M |
| Phathom Pharmaceuticals, Inc.PHAT | 33 | $492.6M |
| Candel Therapeutics IncCADL | 45 | $486.4M |
| Avalo Therapeutics IncAVTX | 56 | $448.7M |
| Cerus CorpCERS | 33 | $400.9M |
| Altimmune IncALT | 54 | $320.1M |
Common questions
What sector and industry is Editas Medicine in?
Editas Medicine is in the Healthcare sector and the Drugs industry.
What is Editas Medicine's Tenet Score?
Editas Medicine's Tenet Score is 27 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.




